Zacks Research Has Weak Estimate for Amarin FY2025 Earnings

Amarin Corporation PLC (NASDAQ:AMRN) – Equities researchers at Zacks Research lowered their FY2025 earnings per share estimates for shares of Amarin in a research report issued on Thursday, January 22nd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of ($2.93) for the year, down from their prior estimate of ($2.03). Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Amarin’s current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($2.71) EPS, Q2 2026 earnings at ($2.55) EPS, Q3 2026 earnings at ($4.22) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($17.05) EPS, Q1 2027 earnings at ($2.77) EPS, Q2 2027 earnings at ($2.77) EPS, Q3 2027 earnings at ($3.33) EPS, Q4 2027 earnings at ($6.46) EPS and FY2027 earnings at ($15.33) EPS.

A number of other research firms also recently weighed in on AMRN. Wall Street Zen downgraded shares of Amarin from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amarin in a report on Wednesday. One analyst has rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell” and a consensus target price of $12.00.

Amarin Trading Down 1.5%

AMRN opened at $16.26 on Monday. The stock’s 50 day simple moving average is $14.98 and its 200-day simple moving average is $15.83. The stock has a market cap of $338.05 million, a PE ratio of -6.53 and a beta of 0.72. Amarin has a 1 year low of $7.08 and a 1 year high of $20.90.

Institutional Trading of Amarin

A number of large investors have recently bought and sold shares of AMRN. Jones Financial Companies Lllp raised its holdings in Amarin by 449,522.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company’s stock worth $815,000 after purchasing an additional 1,811,574 shares during the last quarter. Millennium Management LLC grew its position in shares of Amarin by 192.6% during the 3rd quarter. Millennium Management LLC now owns 132,391 shares of the biopharmaceutical company’s stock worth $2,169,000 after buying an additional 87,147 shares during the period. Jump Financial LLC acquired a new stake in shares of Amarin during the 2nd quarter worth approximately $623,000. George Kaiser Family Foundation bought a new stake in shares of Amarin during the second quarter worth approximately $620,000. Finally, State of New Jersey Common Pension Fund D acquired a new position in Amarin in the third quarter valued at approximately $309,000. 22.25% of the stock is currently owned by institutional investors.

More Amarin News

Here are the key news stories impacting Amarin this week:

• Negative Sentiment: Zacks sharply cut EPS forecasts across Amarin’s near-term and medium-term outlook — including large downward revisions to FY2026 (to -$17.05 from -$3.86) and FY2027 (to -$15.33 from -$3.41) and multiple quarterly EPS drops (e.g., Q4/2026 to -$7.56 from -$1.69, and deep cuts to Q1–Q4 2026–2027). Zacks kept a “Hold” rating, but the far-worse loss projections increase downside risk and likely drove selling pressure. MarketBeat AMRN

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.